Exelixis (EXEL) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Exelixis (EXEL) do?
Exelixis Inc (EXEL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells targeted oncology medicines, primarily cabozantinib formulations, to treat kidney, liver, and thyroid cancers. It generates almost all its revenue from commercializing a single oncology drug across multiple cancer indications. It is worth $16.06B on the market and sold $2.50B over the last year.
- Market cap
- $16.06B
- P/E ratio
- 19.7×
- Annual sales
- $2.50B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 09, 2026
Brands and businesses behind EXEL
- Cabometyx: It is an oral prescription tablet that treats advanced kidney, liver, and thyroid cancers, generating direct product sales.
- Cometriq: It is an oral capsule treatment for progressive medullary thyroid cancer that generates direct pharmaceutical prescription revenue.
EXEL’s flags, in plain English
Each flag is a number from Exelixis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 09, 2026.
Low debt
Low debt, only 9% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Fat Margins
Profit margin of 35.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Wide Gross Margin
Gross margin of 96.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Heavily Shorted
10.8% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about EXEL
How big is Exelixis?
Exelixis’ market cap is $16.06B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.50B: what customers paid the company over the last year, before any costs.
What is EXEL’s P/E ratio?
EXEL’s P/E ratio is 19.7×. Investors pay about 19.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with EXEL?
The company relies on a single compound, cabozantinib, for nearly all of its commercial product revenue. That is one risk on Exelixis’ card. Its first risk flag is Heavily Shorted, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Exelixis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EXEL’s filings on SEC.gov. The Margin Monkey is research, not advice.
